Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost

Carl Erb,1 Ingeborg Stalmans,2 Milko Iliev,3 Francisco José Muñoz-Negrete4 1Eye Clinic Wittenbergplatz, Berlin, Germany; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Ophthalmology Department, University of Bern, Inselspital, Bern, Switzerland; 4S...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Erb C, Stalmans I, Iliev M, Muñoz-Negrete FJ
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/204c16e73afe4faf972faca88aaa6031
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:204c16e73afe4faf972faca88aaa6031
record_format dspace
spelling oai:doaj.org-article:204c16e73afe4faf972faca88aaa60312021-12-02T13:33:13ZReal-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost1177-5483https://doaj.org/article/204c16e73afe4faf972faca88aaa60312021-03-01T00:00:00Zhttps://www.dovepress.com/real-world-study-on-patient-satisfaction-and-tolerability-after-switch-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Carl Erb,1 Ingeborg Stalmans,2 Milko Iliev,3 Francisco José Muñoz-Negrete4 1Eye Clinic Wittenbergplatz, Berlin, Germany; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Ophthalmology Department, University of Bern, Inselspital, Bern, Switzerland; 4Servicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, EspañaCorrespondence: Francisco José Muñoz-NegreteServicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, EspañaTel +34 913 36 80 00Email franciscojmunoz@telefonica.netPurpose: Patient satisfaction is important in the treatment of glaucoma. Suboptimal compliance and impaired long-term outcome are a likely result of poor tolerability. The present multicentre, international, transverse, epidemiological survey was conducted to assess the satisfaction of patients who had received preservative-free latanoprost (PFL) for at least 3 months.Patients and Methods: A total of 1872 patients from 6 European countries, treated with PFL for at least 3 months, were included in this survey. Prior to PFL treatment, patients were to be treatment naïve or currently treated for their glaucoma. During a single routine consultation, patients completed a questionnaire concerning global satisfaction and satisfaction based on tolerability.Results: In total, 76.2% had been previously treated; 69.4% had received preserved and 6.8% preservative-free (PF) topical treatment. After 3 months of PFL treatment, a large majority of patients (95.3%) were satisfied or very satisfied with their PFL treatment and were, overall, significantly (p< 0.0001) more satisfied with PFL than with their previous treatment; 4.2% were either unsatisfied or very unsatisfied. Overall, 97.3% of originally treatment-naïve patients were satisfied (50.1%) or very satisfied (47.2%) with their PFL. Ocular surface disease was diagnosed in 9.2% of patients (n=173) and was mainly mild (76.9%). Patient satisfaction with PFL was very high. Conclusion: PFL may be considered a valuable first-choice treatment in glaucoma patients.Keywords: glaucoma, prostaglandin, preservative-free latanoprost, patient satisfaction, tolerability, tear substitutes, intra-ocular pressure, ocular surface disease, conjunctival hyperaemiaErb CStalmans IIliev MMuñoz-Negrete FJDove Medical Pressarticleglaucomaprostaglandinpreservative-free latanoprostpatient satisfactiontolerabilitytear substitutesintra-ocular pressureocular surface diseaseconjunctival hyperaemiaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 931-938 (2021)
institution DOAJ
collection DOAJ
language EN
topic glaucoma
prostaglandin
preservative-free latanoprost
patient satisfaction
tolerability
tear substitutes
intra-ocular pressure
ocular surface disease
conjunctival hyperaemia
Ophthalmology
RE1-994
spellingShingle glaucoma
prostaglandin
preservative-free latanoprost
patient satisfaction
tolerability
tear substitutes
intra-ocular pressure
ocular surface disease
conjunctival hyperaemia
Ophthalmology
RE1-994
Erb C
Stalmans I
Iliev M
Muñoz-Negrete FJ
Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
description Carl Erb,1 Ingeborg Stalmans,2 Milko Iliev,3 Francisco José Muñoz-Negrete4 1Eye Clinic Wittenbergplatz, Berlin, Germany; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Ophthalmology Department, University of Bern, Inselspital, Bern, Switzerland; 4Servicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, EspañaCorrespondence: Francisco José Muñoz-NegreteServicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, EspañaTel +34 913 36 80 00Email franciscojmunoz@telefonica.netPurpose: Patient satisfaction is important in the treatment of glaucoma. Suboptimal compliance and impaired long-term outcome are a likely result of poor tolerability. The present multicentre, international, transverse, epidemiological survey was conducted to assess the satisfaction of patients who had received preservative-free latanoprost (PFL) for at least 3 months.Patients and Methods: A total of 1872 patients from 6 European countries, treated with PFL for at least 3 months, were included in this survey. Prior to PFL treatment, patients were to be treatment naïve or currently treated for their glaucoma. During a single routine consultation, patients completed a questionnaire concerning global satisfaction and satisfaction based on tolerability.Results: In total, 76.2% had been previously treated; 69.4% had received preserved and 6.8% preservative-free (PF) topical treatment. After 3 months of PFL treatment, a large majority of patients (95.3%) were satisfied or very satisfied with their PFL treatment and were, overall, significantly (p< 0.0001) more satisfied with PFL than with their previous treatment; 4.2% were either unsatisfied or very unsatisfied. Overall, 97.3% of originally treatment-naïve patients were satisfied (50.1%) or very satisfied (47.2%) with their PFL. Ocular surface disease was diagnosed in 9.2% of patients (n=173) and was mainly mild (76.9%). Patient satisfaction with PFL was very high. Conclusion: PFL may be considered a valuable first-choice treatment in glaucoma patients.Keywords: glaucoma, prostaglandin, preservative-free latanoprost, patient satisfaction, tolerability, tear substitutes, intra-ocular pressure, ocular surface disease, conjunctival hyperaemia
format article
author Erb C
Stalmans I
Iliev M
Muñoz-Negrete FJ
author_facet Erb C
Stalmans I
Iliev M
Muñoz-Negrete FJ
author_sort Erb C
title Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
title_short Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
title_full Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
title_fullStr Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
title_full_unstemmed Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
title_sort real-world study on patient satisfaction and tolerability after switching to preservative-free latanoprost
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/204c16e73afe4faf972faca88aaa6031
work_keys_str_mv AT erbc realworldstudyonpatientsatisfactionandtolerabilityafterswitchingtopreservativefreelatanoprost
AT stalmansi realworldstudyonpatientsatisfactionandtolerabilityafterswitchingtopreservativefreelatanoprost
AT ilievm realworldstudyonpatientsatisfactionandtolerabilityafterswitchingtopreservativefreelatanoprost
AT munoznegretefj realworldstudyonpatientsatisfactionandtolerabilityafterswitchingtopreservativefreelatanoprost
_version_ 1718392841220128768